TLSHAA
Telstra Group Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
3.75% Fixed Mat 04-May-2031 Min Cons $5Ht Nc
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in TLSHAA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in TLSHAA
N/A
TLSHAA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in TLSHAA also invest in...
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
12.49%
📊 Share price
$15.92 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
AUST.AX was created on 2015-11-09 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The investment objective of the Fund is: to provide exposure to a broadly diversified portfolio of Australian shares, generally consisting of approximately 200 of the largest equity securities on the ASX, weighted by their market capitalisation, and to reduce the volatility of the Funds equity investment returns and cushion downside risk
🙌 Performance (5Yr p.a)
-0.03%
📊 Share price
$17.25 AUD
⛳️ DIVERSIFIED
💸 FINANCIALS
🇦🇺 AUSTRALIA
IVV
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
20.00%
📊 Share price
$62.69 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
NDQ
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
26.88%
📊 Share price
$50.12 AUD
🇺🇸 UNITED STATES
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
FUEL.AX was created on 2016-06-16 by BetaShares. The fund's investment portfolio concentrates primarily on energy equity. The fund aims to track the performance of an index (before fees and expenses) that comprises the largest global energy companies (ex-Australia), hedged into Australian dollars.
🙌 Performance (5Yr p.a)
1.02%
📊 Share price
$6.00 AUD
🇦🇺 EX AUSTRALIA
Want more shares? Try these...
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. The company operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. The company operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.
🙌 Performance (5Yr p.a)
308.77%
📊 Share price
$24.74 AUD
🧬 BIOTECHNOLOGY
TLS
Telstra Group Ltd. engages in the provision of telecommunications and technology services. The company is headquartered in Melbourne, Victoria and currently employs 33,761 full-time employees. The firm's Telstra Consumer segment provides telecommunication and technology products and services to consumer customers in Australia using mobile and fixed network technologies. Its Telstra Business segment provides telecommunication and technology products and services to small and medium businesses. Its Telstra Enterprise Australia segment provides telecommunication services, advanced technology solutions and others. Its Telstra International segment provides telecommunication, media and technology products and services to consumer, business and government customers in the South Pacific through its Digicel Pacific business. Its Networks, IT and Product segment's operations include Global Networks and Technology, and Product and Technology. Its Telstra InfraCo segment provides telecommunication products and services delivered over its networks.
🙌 Performance (5Yr p.a)
1.69%
📊 Share price
$3.98 AUD
📞 COMMUNICATIONS